[7] [8] Retatrutide, conversely, enhances insulin secretion and improves glycaemic control through its GLP-1 and GIP receptor activity
It is essential to balance the potential benefits of these medications with their risks, ensuring that individuals receive the most effective and safe treatment for their unique needs
In the STEP-1 trial (N=1,961), adults receiving semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo [1]
Fatigue and general discomfort, which tend to resolve with time
The Mirena IUD was the intrauterine device on the market offering protection against pregnancy for a span of up to eight years
In this context, a correct food intake must be able to prevent malnutrition in the first months of life